Andere talen AlzeCure Pharma AB

Aandelen

ALZCUR

SE0010133785

Vertraagde tijd Nasdaq Stockholm Andere beurzen 10:55:44 22-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,04 ^SEK	+2,00%		+14,29%	-34,41%

14/05	AlzeCure Pharma AB (publ) keurt de verkiezing van Jan Lundberg als nieuw gewoon lid van de raad van bestuur goed	CI
25/04	AlzeCure Pharma AB (publ) rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

AlzeCure Pharma AB - Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg elected as a new board member	16/05
Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg elected as a new board member	15/05
AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors	14/05
Communiqué from the annual general meeting of AlzeCure Pharma on 14 May 2024	14/05
AlzeCure reports anti-inflammatory effects with NeuroRestore ACD856 with relevance to Alzheimer's leading to new patent application	13/05
AlzeCure Pharma publishes prospectus	29/04
AlzeCure publishes its interim report for January – March 2024	25/04
AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board	10/04
Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).	10/04
AlzeCure Pharma publishes its Annual Report for 2023	04/04
AlzeCure presents new data regarding the TrkA-NAM pain project at IASP 2024	03/04
AlzeCure Pharma AB Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024	03/04
AlzeCure to partake in Redeye Theme, Alzheimer on March 21	15/03
AlzeCure to partake in Redeye Theme: Alzheimer on March 21	14/03
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference	07/03
AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer's conference	07/03
AlzeCure Pharma AB Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's	05/03
AlzeCure publishes clinical results supporting continued development of NeuroRestore ACD856 against Alzheimer's	05/03
AlzeCure's Alzheimer's project NeuroRestore ACD856 is granted an additional patent	29/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen AlzeCure Pharma AB

Aandelen

ALZCUR

SE0010133785

Andere talen

Filters